Credent Connect N Care has raised Rs 26.53 crore from anchor investors, including Abakkus and Motilal Oswal, ahead of its public issue. The SME IPO opens for subscription on August 13, with a price band set at Rs 179–189 per share.
Credent Connect N Care, a healthcare logistics provider, has finalized its anchor book allocation, raising Rs 26.53 crore just a day before its Initial Public Offering (IPO). The company secured this investment from 10 anchor participants, including prominent names like Abakkus Asset Manager, Motilal Oswal Financial Services, and 360 ONE, with shares allotted at the upper price band of Rs 189.
The public offering is scheduled to open for subscription on August 13 and will close on August 17, 2026. This is an SME (Small and Medium Enterprise) issue, meaning shares will be listed on the NSE SME platform. The company aims to raise a total of Rs 93.89 crore through the issuance of 49.68 lakh fresh shares, with the price range fixed between Rs 179 and Rs 189 per share. Investors should note that for this SME IPO, the minimum lot size is 1,200 shares, requiring a minimum investment of Rs 2,26,800 for retail participants at the upper price limit.
Financial performance leading up to the IPO shows a sharp increase in growth. For the financial year ended March 2026, the company reported a profit of Rs 18.4 crore, a significant rise from Rs 2.2 crore in the previous year. Revenue from operations also climbed to Rs 214.2 crore, compared to Rs 77.9 crore in FY25. The company specializes in business-to-business healthcare logistics, focusing on moving diagnostic samples and reagents between laboratories and healthcare centers.
The company plans to use the funds raised to improve its financial flexibility and support growth. A portion of the proceeds will go toward working capital needs for its subsidiary, Credent Healthcare, while other funds are earmarked for purchasing machinery and repaying existing debt.
While the financials show a positive trend, investors should review the specific business risks disclosed in the company’s filings. A primary concern is the company's high dependency on its top 10 customers. Since these large clients do not provide long-term guaranteed commitments, the loss or reduction of business from these key accounts could directly impact revenue. Additionally, the business model is working capital intensive, meaning a significant portion of its assets are tied up in payments owed by clients.
Operational risks also remain a factor. Because the business involves the physical transport of sensitive medical samples and reagents, any delays, damage, or contamination during transit could disrupt service levels and potentially lead to contract penalties or terminations. The company’s growth is also tied to the outsourcing demand from diagnostic laboratories, which can fluctuate based on health sector trends.
Looking ahead, the market will monitor the subscription demand when the IPO opens. The listing is tentatively planned for August 20, 2026. Investors should closely follow the post-listing performance and the company’s ability to manage its working capital and client concentration risks in the coming quarters.